Τόμος 1 (1987) – Τεύχος 1 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 1 (1987) – Issue 1 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

3.         Snyder, F.: Chemical and biochemical aspects of platelet activating factor: a novel class of acetylated ether-linked choline-phospholipids. Med. Res. Rev. 5: ‘107 (1985)

4.         Camussi, G., Aglietta, M., Malavasi, F., Tetta, C., Piacibello, W., Bussoli/io, F.: Platelet-activiting factor. In: Glomerular Injury 300 Years after Morgagni (Bertani, T., Remuzzi, G., eds), p. 89, Wichtig Ed., 1983

5.         Bussolino, F„ Benveniste, J.: Pharmacological modula¬tion of platelet-activating factor (PAF) release from rabbit leucocytes. I. Role of cAMP. Immunology 40: 367 (1980)

6.         Bussolino, F,  Gremo, F., Tetta, C., Pescarmona, G.P., Camussi, G.: Production of Platelet-Activating Factor (PAF) from chick retina stimulated by neurotransmitters. The 6th Int. Conference on Prostaglandins and related compounds. Florence (Italy), Jone, 3-6, 1986

7.         Bussolino, F„ Biffignandi, P.’, Arese, P.: Inhibitory effect of calcium dobesilate on the production of PAF by the EA 926 cell line. 4th European Conference on Clinical Haemorrheology, Siena, June, 20-25, 1985

8.         Bussolino, F„ Arese, P.: Pharmacological modulation of PAF production from EA 926 cell line. International Symposium “Leukotrienes and PAF-acether 85”. Paris, Sept. 27, 1985

9.         Camussi, G„ Aglietta, M., Malavasi, F., Tetta, C., Piaci- bello, W., Bussolino, F.: Platelet-activating factor release from human endothelial cells in culture. J. Immunol. 131: 2397 (1983)

10.       Camussi, G., Bussolino, F., Tetta, C., Benveniste, J.. Vercellone, A.: Platelet-activating factor and glomerulonephritis. In: Hemostasis, Prostaglandins and Renal Disease (Remuzzi G, Mecca G., de Gaetano G., eds), p. 133, Raven Press, New York, 1980

11.       Camussi, G., Bussolino, F., Tetta, C., Brusca, R., Ragni, R.: The binding of platelet-activating factor (PAF) to polymorphonuclear neutrophils (PNM) as a trigger of immune-induced PNM aggregation. Pan. Med. 22: 117 (1980)

12.       Pace, C., Deeming, Κ., Sanjar, S., Morley, J.: Evidence favouring PAF, rather than leukotrienes, as the primary agency of asthma pathology. International Symposium “Leucotrienes et PAF-acether 85”, Paris 27 Sept. 1985

13.       Braquet, P., Vidal, R., Braquet, M., Deby, C., Bourgain, R.H., Vergaftig, B.B.: Platelet-activating factor induces acute modification of the rabbit retinal vessels imitating human retinopathies. In: Platelet Activating Factor and Structurally Related Ether Lipids (J. Benveniste, B. Arnoux, eds), p. 223, Elsevier Science Publ., New York, 1983

14.       Barras, J.P. and Graf, C:; Effects of medication on blood and plasma viscosity in diabetic subjects with retinopathy. In: Pathogenetic concepts of diabetic microangio- pathy (Georg Thieme Verlag, Eds), Volume Nr. 11, p. 120, 1981

15.       Cunha-Vaz, S.G.: Studies on the pathophysiology of diabetic retinopathy. The blood-retinal barrier in diabetes. Diabetes 32 (Suppl. 2): 20 (1983)

16.       Goto, Y., Kakizaki, M., Toyota, T., Oikawa, S., Oikawa, N., Yagihashi, S.: Inhibition of thickening of glomerular capillary basement membrane in spontaneously diabetic rats. In [Abe H., Hoshi M., eds): Diabetic Microangiopathy, p. 433, S. Karger, Basel, 1983

17.       Krzywanck, H.J., Breddin, Κ.: Platelet aggregation as a risk factor in diabetic subjects. In: Pathogenetic concepts of diabetic microangiopathy (Georg Thieme Verlag, Eds), Volume Nr. 11, p. 11, 1981

18.       Porta, M., Towsend, C., Clover, G.M, Nanson, M., Alderson, A.R., McCraw, A., Kohner, E.M.: Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 20: 597 (1981)

19.       Williamson, J.R., Gardner, R.A., Boylan, C.W., Carroll, G.L., Chang, Κ., Marvell, J.S., Gonen, B., Kilo, C., Tran- Son-Tay, R., Suter, S.P.: Microrrheologic investigation of erythrocyte deformability in diabetes mellitus. Blood 65: 283 (1985)

20.       Doly, M., Braquet, P., Bonhomme, B.: Inhibition of PAF- acether-induced disturbances of electroretinograhic waves by specific PAF-acether antagonists. The 6th Inter. Conference on Prostaglandins and related compounds, Florence (Italy), June, 3-6, 1986

21.       Bussolino,’ F., Aglietta, M., Sanavio, F., Stacchini, A., Lauri, D„ Camussi, G.: Alkylether phosphoglycerides modify calcium homeostasis into human endothelial cells. J. Immunol. 135: 2748 (1985)

22.       Snyder, F., Blank, M.L., Lee, T.C., Malone, B., Robinson, M., Woodant, D.: Alkylacetylglycerols versus “acyr-PAF as precursors in PAF biosynthesis and the role of arachidonic acid. International Symposium “Leucotrienes et PAF-acether 85”, Paris, 27 Sept. 1985

23.       Gtoviczki, P., Fowl, R.J., Holier, L.H., Dewanjee, M.K., Plate, G., Kaye, M.P.: Prevention of platelet deposition by ibuprofen and calcium dobesilate in expanded polytetrafluoroethylene vascular grafts. Am. J. Surg. 150: 589 (1985)

24.       Michal, M., Giessinger, N.: Effect of calcium dobesilate and its interaction with aspirin on thrombus formation in vivo. Thrombosis Res. 40: 215 (1985)

25.       Salama Benarroch, I., Brodsky, M., Rubinstein, A., Viggiano, C.( Salama, E.A.: Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res. 17: 131 (1985)

26.       Schmitz-Valckenberg, P.: Therapeutic consequences in diabetic retinopathy. Therapiewoche 34 (37): 5221 (1984)

27.       Vojnikovic, B.: Hyperviscosity in whole blood, plasma and aqueous humor decreased by Doxium (calcium dobesilate) in diabetics with retinopathy and glaucoma: a double- blind controlled study. Ophthalmic Res. 16: 150 (1984).